Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways

Magn Reson Med. 1998 Aug;40(2):236-42. doi: 10.1002/mrm.1910400209.

Abstract

Human transferrin was covalently coupled to ultrasmall superparamagnetic iron oxide (USPIO) particles, and the transferrin-USPIO obtained was investigated in vivo in experimental SMT/2A tumor-bearing rats (rat mammary carcinoma). Physicochemical characterization showed an overall size of 36 nm (DLS) with a core size of 5 nm (TEM). Relaxivities were R1 = 23.6 and R2 = 52.1 liter/mmol.s (0.47 T). Bound transferrin was 280 micrograms/mg of iron. Pharmacokinetic investigations revealed a half-life of 17 min in normal rats. The MR evaluation of tumor signal intensity over time showed a 40% (range 25-55%) signal reduction 150 min after injection with the reduction persisting for at least 8 h. Control experiments using the parent USPIO compound or USPIO labeled with a nonspecific human serum albumin (HSA-USPIO) showed a change of only 10% (range 5-15%) in tumor signal intensity over time. The results demonstrate that a combination of the USPIO relaxivity properties with the specificity of transferrin-mediated endocytosis allows in vivo detection of tumors by MR imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Contrast Media* / pharmacokinetics
  • Dextrans
  • Female
  • Ferrosoferric Oxide
  • Humans
  • Iron* / pharmacokinetics
  • Magnetic Resonance Imaging*
  • Magnetite Nanoparticles
  • Male
  • Mammary Glands, Animal / pathology
  • Mammary Neoplasms, Experimental / pathology*
  • Oxides* / pharmacokinetics
  • Rats
  • Receptors, Transferrin / analysis*
  • Tumor Cells, Cultured

Substances

  • Contrast Media
  • Dextrans
  • Magnetite Nanoparticles
  • Oxides
  • Receptors, Transferrin
  • ferumoxtran-10
  • Iron
  • Ferrosoferric Oxide